Inhibrx Earning Date (INBX)

USA |NASDAQ |USD

INBX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 2, 2022 Jun 2022 - - $-0.55
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 2, 2022 Jun 2022 - - $918.00K

Inhibrx's next earnings date is Tuesday, Aug 2, 2022 for the fiscal quarter ending Jun 2022.

INBX Earnings Date & History Chart

INBX Earnings & Revenue Forecast

INBX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $-2.47 $-2.87 $-2.27

INBX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 1 / 0 $-2.50 $-2.67 $-2.42

INBX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $1.77M $0.00 $4.10M

INBX Earnings Date & Revenue History

INBX Earnings History

|
Show More
Show More

INBX Revenue History

|
Show More
Show More

Inhibrx Next Earnings Date & Report

INBX Next Earnings Date & Report Preview: Jun 2022 (FQ)

INBX's next earnings date is Tuesday, Aug 2, 2022 for the fiscal quarter ending Jun 30, 2022.

Inhibrx Previous Earnings Dates & Reports

INBX Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Inhibrx's previous earnings date was May 11, 2022 for its fiscal quarter ended Mar 31, 2022.

INBX Previous Earnings Date & Report Recap: Dec 2021 (FY)

Inhibrx's previous annual earnings date was Feb 28, 2022 for its fiscal year ended Dec 31, 2021.

INBX's earnings per share (EPS) was $-2.15, beating the consensus analysts forecast of $-2.28 by -5.70% , and lower than the previous year's EPS (Dec 2020) by 44.36%.

Revenues were $7.12M, better than the forecast of $2.15M by 231.40%, and down by -44.72% from previous year's revenue.

The company reported a net income of $-81.77M.

Inhibrx reported a free cash flow of $-81.19M for its fiscal year, compared to $-49.33M a year ago.

The company ended the fiscal year with $70.47M in total debt, an increase of 129.19% compared to the previous year.